Bristol-Myers Squibb Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Inhibitex, Inc.

Bristol-Myers Squibb Company BMY announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended for its tender offer for Inhibitex, Inc. INHX has expired. Bristol-Myers Squibb initiated on January 13, 2012, through its wholly-owned subsidiary Inta Acquisition Corporation, a cash tender offer to purchase all outstanding shares of common stock of Inhibitex for $26.00 per share.